How to Help Your Patients Save Money on Depo-Estradiol: A Provider's Guide to Savings Programs

The discontinuation of brand-name Depo-Estradiol has created not only an access challenge for patients but also a cost landscape that many providers are not yet fully equipped to navigate. Patients who were previously covered by insurance for the brand now face uncertainty about coverage for compounded versions. This guide provides a comprehensive framework for helping your patients afford estradiol cypionate injection in 2026.

Understanding the Current Cost Landscape

Before you can help your patients, it's important to understand where costs currently stand:

Brand Depo-Estradiol (discontinued): Was $260-$310 per 5 mL vial (5 mg/mL) retail. With GoodRx: as low as $262. With SingleCare: approximately $254. Pfizer RxPathways provided the drug at no cost for eligible uninsured patients.

Compounded estradiol cypionate (current option): Typically $30-$80 per 5 mL vial from compounding pharmacies — a significant reduction from brand pricing. However, insurance coverage for compounded products is much less predictable.

The good news: the compounded alternative is genuinely less expensive. The challenge is that some patients may lose insurance coverage for the compounded version if their plan only covered the brand, and the administrative burden of navigating coverage falls disproportionately on your practice and your patients.

Strategy 1: Direct Patients to Compounding Pharmacies with Competitive Pricing

The most impactful savings action for most patients is simply accessing compounded estradiol cypionate rather than any commercial brand. At $30-$80 per vial, compounded estradiol cypionate is dramatically less expensive than the $260-$310 brand it replaces.

Recommendations for building your compounding pharmacy referral network:

Identify 2-3 PCAB-accredited compounding pharmacies in your region and request their pricing for estradiol cypionate 5 mg/mL, 5 mL vial

Identify at least one 503B national mail-order outsourcing facility for patients who cannot access local compounding pharmacies

Compare cash pricing between pharmacies — prices vary widely, and some 503B facilities offer very competitive cash pricing

Create a one-page pharmacy referral handout that includes pricing, contact information, and whether insurance is accepted

Strategy 2: Navigate Insurance Coverage for Compounded Estradiol Cypionate

Insurance coverage for compounded medications requires careful navigation:

Commercial insurance: Most commercial plans cover hormone replacement therapy, but coverage for compounded (vs. commercially manufactured) products is inconsistent. Some plans will cover compounded estradiol cypionate if there is documented medical necessity and no commercially available equivalent. Your practice team can help by:

Writing a letter of medical necessity stating that brand Depo-Estradiol has been discontinued and no commercially manufactured equivalent is available

Submitting prior authorization requests with documentation of medical need and unavailability of brand product

Appealing denials with supporting clinical documentation if the initial request is denied

Medicare Part B: Estradiol injections administered in your office setting may be billable under Medicare Part B as a medical benefit (B-covered drug). If your patients receive injections in-clinic, billing Part B rather than routing through the Part D pharmacy benefit may provide coverage for compounded formulations that Part D would otherwise deny. Consult with your billing team about appropriate coding.

Medicare Part D: Part D coverage for compounded medications is extremely limited. In-home self-injection patients are unlikely to have Part D coverage for compounded estradiol cypionate. Direct these patients to cost-saving strategies below.

Strategy 3: Patient Assistance Program Guidance

Pfizer's RxPathways program (pfizerrxpathways.com, 1-877-744-5675) historically offered Depo-Estradiol at no cost to eligible uninsured patients. With the brand discontinued, the applicability of this program to compounded versions is unclear. However, providers should still investigate and document referrals to this program.

Additional patient assistance resources to document and share:

NeedyMeds.org: Comprehensive database of patient assistance programs for specific drugs and therapeutic classes

PPARX.org: Partnership for Prescription Assistance — helps patients identify manufacturer programs

State pharmaceutical assistance programs: Many states offer programs for uninsured or underinsured patients. Check your state health department website.

Federally Qualified Health Centers (FQHCs): For uninsured patients, FQHCs provide sliding-scale care and may have access to hormone therapy at reduced cost

Strategy 4: Prescribe the Most Cost-Effective Formulation for Each Patient

Not all patients require injectable estradiol. For patients who switched to Depo-Estradiol primarily for convenience (monthly injections vs. daily pills), the current access challenges and any cost concerns may be a reasonable time to reassess whether a different formulation would be equally effective and more accessible:

Generic oral estradiol: Available at most pharmacies for $4-$15 per month — the most cost-effective option for menopausal patients without specific injectable indications

Generic estradiol patch: When available, generic patches are significantly less expensive than brand-name patches. Note: patches are in shortage in 2026.

Estradiol gel: EstroGel and Divigel are available and generally well-covered by commercial insurance; Divigel has a manufacturer savings card

For gender-affirming care patients and those with hypogonadism who specifically need injectable estradiol, the clinical rationale for the injectable route is stronger. For these patients, focus on identifying the most affordable compounding pharmacy source.

Strategy 5: Streamline Your Practice's Prior Auth Process

Prior authorizations for compounded medications can be approved if properly documented. Build a standardized PA template for compounded estradiol cypionate that includes:

Documentation that brand Depo-Estradiol is discontinued and no commercially manufactured substitute is available

Patient's diagnosis and indication for injectable estrogen (ICD-10 codes for menopause, hypogonadism, gender dysphoria as applicable)

Clinical notes supporting the need for the injectable route (e.g., difficulty with patch adherence, GI intolerance to oral, preference for injectable in GAHT)

Supporting serum estradiol levels and treatment response documentation

How medfinder Can Support Your Practice

Beyond finding availability, medfinder for Providers helps reduce the administrative burden on your practice when patients are struggling to find specialty medications. By directing patients to medfinder, you minimize the number of frustrated callbacks your front desk receives from patients who can't find their prescription. For more on supporting your patients through the Depo-Estradiol access situation, see our full provider access guide.

Summary: Provider Action Checklist for Cost Management

Build a compounding pharmacy referral list with current pricing for estradiol cypionate 5 mg/mL

Educate patients that compounded estradiol cypionate is typically $30-$80/vial (vs. $260-$310 for the discontinued brand)

Create a standardized prior authorization template for compounded estradiol cypionate

Refer uninsured patients to Pfizer RxPathways, NeedyMeds.org, and state pharmaceutical assistance programs

Consider oral estradiol or estradiol gel as cost-effective alternatives for patients where injectable route is not clinically essential

For Medicare patients receiving in-office injections, explore Part B billing for compounded estradiol cypionate

Direct patients to medfinder for Providers to reduce administrative burden on your front desk